The ARL1 Knockout HEK293T Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for detailed investigation of ARL1-dependent processes. This product utilizes a human embryonic kidney 293T (HEK293T) host background with targeted disruption of the ARL1 gene, which encodes a small GTPase of the ARF family. The polyclonal format provides a heterogeneous pool of loss-of-function cells, enabling robust analysis of gene function without the clonal selection bottlenecks associated with single-cell-derived lines. CRISPR/Cas9-mediated gene disruption abrogates endogenous ARL1 expression, offering a versatile model for studying its roles in intracellular membrane dynamics.
The HEK293T cell line is a derivative of the classic HEK293 line, stably expressing the SV40 large T antigen to enhance episomal replication of plasmids carrying the SV40 origin. These adherent epithelial cells are widely employed as a mammalian expression system for high-level protein production, viral packaging for lentivirus and retrovirus generation, and fundamental cell biology research. Their rapid growth, ease of transfection, and well-characterized proteome make HEK293T an ideal chassis for dissecting secretory and endocytic pathways, where ARL1 plays a central regulatory role at the trans-Golgi network (TGN).
ARL1 functions as a molecular switch, cycling between GDP- and GTP-bound states to control membrane trafficking. GTP-bound ARL1 is specifically recruited to the TGN, where it interacts with downstream effectors including the golgin subfamily members golgin-97 and GCC185, as well as the GARP complex, COPI vesicles, and Arfaptin-2. This recruitment is regulated by upstream guanine nucleotide exchange factors (GEFs) and phosphatidylinositol 4-phosphate, which influence ARL1 activation and membrane localization. ARL1-GTP orchestrates vesicle tethering at the TGN, facilitating retrograde transport from endosomes to the Golgi and maintaining Golgi ribbon architecture. The gene product also associates with SCOCO and RAB6IP1, integrating ARF-family signaling with coordinated RAB GTPase cascades and SNARE-mediated fusion events.
In the HEK293T context, knockout of ARL1 is expected to profoundly perturb TGN organization and cargo sorting. Loss of ARL1 disrupts the normal recruitment of golgin-97 and GCC185 to the TGN, impairing vesicle tethering and retrograde trafficking. This may lead to mistrafficking of Golgi-resident enzymes, altered glycosylation patterns, and defective recycling of cell surface receptors. Given the emerging links between Golgi dysfunction and pathologies such as cancer cell migration and neurodegeneration, this knockout model provides a valuable platform to dissect mechanisms underlying these conditions. Additionally, since HEK293T cells support robust viral replication, ARL1 disruption can illuminate its potential contributions to viral assembly and egress, which depend on functional secretory pathways.
Researchers can employ this polyclonal ARL1 knockout model in a broad range of assays. Western blotting and RT-qPCR confirm target-gene disruption, while immunofluorescence with markers such as GM130 and TGN46 permits visualization of Golgi morphology changes. Vesicular transport assays, co-immunoprecipitation of ARL1 interactors (e.g., Arfaptin-2, SCOCO), and flow-cytometric monitoring of surface receptors enable functional readouts. These cells are suited for investigating Golgi trafficking, membrane dynamics, golgin biology, cancer cell migration, and viral replication studies. For further details or technical assistance, please contact Ascent Research.
